Molecular basis of drug resistance: Epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors

8Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Over the past decade, several kinase inhibitors have been approved based on their clinical benefit in cancer patients. Unfortunately, in many cases, patients develop resistance to these agents via secondary mutations and alternative mechanisms. To date, several major mechanisms of acquired resistance, such as secondary mutation of the epidermal growth factor receptor (EGFR) gene, amplification of the MET gene and overexpression of hepatocyte growth factor, have been reported. This review describes the recent findings on the mechanisms of primary and acquired resistance to EGFR tyrosine kinase inhibitors and acquired resistance to anaplastic lymphoma kinase inhibitors, primarily focusing on non-small cell lung carcinoma. Copyright © 2013 The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Cite

CITATION STYLE

APA

Yang, S. H. (2013). Molecular basis of drug resistance: Epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors. Tuberculosis and Respiratory Diseases. Korean National Tuberculosis Association. https://doi.org/10.4046/trd.2013.75.5.188

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free